GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gufic Biosciences Ltd (NSE:GUFICBIO) » Definitions » Deferred Tax

Gufic Biosciences (NSE:GUFICBIO) Deferred Tax : ₹0 Mil (TTM As of Sep. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Gufic Biosciences Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Gufic Biosciences's change in deferred tax for the three months ended in Sep. 2024 was ₹0 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Sep. 2024 was ₹0 Mil.

Gufic Biosciences Deferred Tax Historical Data

The historical data trend for Gufic Biosciences's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gufic Biosciences Deferred Tax Chart

Gufic Biosciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Deferred Tax
Get a 7-Day Free Trial Premium Member Only Premium Member Only 74.38 134.80 309.98 270.16 295.36

Gufic Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Gufic Biosciences Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gufic Biosciences Deferred Tax Related Terms

Thank you for viewing the detailed overview of Gufic Biosciences's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Gufic Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gufic Biosciences Ltd (NSE:GUFICBIO) » Definitions » Deferred Tax
Comparable Companies
BOM:512529 BOM:524164 BOM:524372 NSE:RPGLIFE BOM:530549 BOM:532612 BOM:506690 BOM:532300 BOM:524735 BOM:590006 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
509079:India
Address
SM House, 11 Sahakar Road, 1st to 4th Floor, Vile Parle (East), Mumbai, MH, IND, 400 057
Website
https://www.gufic.com
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare; Criticare Life; Ferticare; Spark; Herbal and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral and a proton-pump inhibitor. It derives maximum revenue from India.

Gufic Biosciences Headlines

No Headlines